Cardiac Dimensions, Inc. is currently enrolling patients in the PRIME
(Percutaneous Repair in Functional Mitral Regurgitation) Registry study, a
prospective, multicenter post-market registry that builds on the clinical
experience from Cardiac Dimensions’ AMADEUS,
TITAN and TITAN II studies of the
CARILLON® Mitral Contour System®. Long-term safety and efficacy will be
evaluated in the PRIME Registry through the assessment of hemodynamics,
functional capacity, heart failure hospitalizations as well as quality of life.
T
he
PRIME Registry study is being undertaken at multiple sites in Europe. United States
residents are not eligible for the PRIME Registry study.